BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies
January 12 2021 - 5:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT)
(OTCQB:BCTXF),
a clinical-stage
biotechnology company specializing in targeted immunotherapies for
advanced breast cancer, is pleased to announce that the Company
will present a poster at the 2021 Keystone Symposia, “Emerging Cell
Therapies: Realizing the Vision of NextGen Cell Therapeutics,” a
virtual scientific conference which is being held Jan. 25-27, 2021.
BriaCell will deliver a presentation with poster
highlighting the clinical and pathological findings of its lead
candidate, Bria-IMT™, a novel immunotherapy for advanced breast
cancer, as monotherapy (i.e. the Bria-IMT™ regimen alone) and a
Phase I/IIa clinical study of Bria-IMT™ in combination with immune
checkpoint inhibitors including pembrolizumab (KEYTRUDA®;
manufactured by Merck & Co., Inc.), and more recently, Incyte’s
INCMGA00012 (under corporate collaboration with Incyte
Corporation).
The details of the
presentation are as follows:
Poster
Title: Personalized off-the-shelf whole cell immunotherapy
for cancer
Date and
Time: January 25, 2021 10:00 AM ET - January 27, 2021 8:00
PM ET
A copy of the poster will be posted at the
following: https://briacell.com/novel-technology/scientific-publications/.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding
Forward-Looking Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024